Skip to main content

Table 6 Univariate and multivariate analysis with post-recurrence survival

From: The effect of smoking on biological change of recurrent breast cancer

ParametersUnivarite analysisMultivarite analysis
Hazard ratio95% CIp valueHazard ratio95% CIp value
Age at operation (years old)
 ≤ 60 vs > 600.8780.173–3.9930.865   
Tumor size (cm)
 ≤ 21.8 vs > 21.81.4640.322–7.4450.616   
Lymph node metastasis
 Negative vs positive1.6190.230–7.5870.581   
Estrogen receptor (ER) of primary tumor
 Negative vs positive0.3260.072–1.6610.164   
Progesterone receptor (PgR) of primary tumor
 Negative vs positive0.3410.075–1.7480.182   
HER2 of primary tumor
 Negative vs positive8.2340.405–65.2390.136   
Ki67 of primary tumor
 ≤14% vs > 14%0.7020.154–3.5810.649   
Intrinsic subtype HRBC
 No vs yes0.2610.057–1.3280.1000.6910.093–5.9860.718
Intrinsic subtype HER2BC
 No vs yes8.2340.405–65.2390.136   
Intrinsic subtype TNBC
 No vs Yes2.4230.347–11.2890.325   
Chemotherapy after surgery
 No/yes4.1330.910–20.9990.0653.6920.537–24.6570.176
Endocrine therapy after surgery
 No vs yes0.7700.165–5.4030.760   
Radiation therapy after surgery
 No vs yes2.2790.448–10.3720.297   
Trastuzumab after surgery
 No vs yes11.9240.589–93.4870.0900.5520.014–23.1530.735
No-treatment after surgery
 No vs yes0.245   
Age at recurrence (years old)
 ≤ 62 vs > 621.0080.197–4.6210.992   
Recurrence site biopsied
 Local, regional lymph node vs Distant metastasis8.5271.114–52.0100.0416.9620.312–73.3590.178
Change of ER in recurrence
 The other vs negative conversion2.1940.116–12.9670.509   
Change of PgR in recurrence
 No change vs negative conversion0.5830.083–2.7420.509   
Change of HER2 in recurrence
 No change vs positive conversion0.203   
Change of intrinsic subtype in recurrent tumor
 No vs yes1.1940.063–7.0800.873   
Disease free survival
 ≤ 792 vs > 7920.9360.177–4.4860.934   
Smoker
 No vs Yes0.0520.118
  1. CI confidence intervals, HER2 human epidermal growth factor receptor 2, HRBC hormone receptor positive breast cancer, HER2BC human epidermal growth factor receptor 2-enriched breast cancer, TNBC triple negative breast cancer